A patient-level meta-analysis of studies evaluating vagus nerve stimulation therapy for treatment-resistant depression

Medical Devices: Evidence and Research

Volumn 6, Issue 1, 2013, Pages 17-35

  Berry, Scott M ^a   Broglio, Kristine ^a   Bunker, Mark ^b   Jayewardene, Amara ^b   Olin, Bryan ^b   Rush, A John ^c  

^a BERRY CONSULTANTS   (United States)

^b Cyberonics Inc   (Italy)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Bayesian meta analysis; Remission rate; Response rate; Treatment resistant depression; Vagus nerve stimulation; VNS therapy

Indexed keywords

META-ANALYSIS; REMISSION RATE; RESPONSE RATE; TREATMENT-RESISTANT DEPRESSION; VAGUS NERVE; VNS THERAPY;

HIERARCHICAL SYSTEMS; SURVEYS;

PATIENT TREATMENT;

LITHIUM; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; CHRONIC DISEASE; CHRONICITY; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; ELECTROCONVULSIVE THERAPY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; META ANALYSIS; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY (TOPIC); NERVE STIMULATOR; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESISTANT DEPRESSION; TREATMENT RESPONSE; VAGUS NERVE STIMULATION;

EID: 84874689023     PISSN: None     EISSN: 11791470     Source Type: Journal    
DOI: 10.2147/MDER.S41017     Document Type: Review

References (44)

1. WHO: Depression [webpage on the Internet]. Geneva: World Health Organization. Available from: http://www.who.int/mediacentre/factsheets/fs369/en/index.html. Accessed January 24, 2012.
2. Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen HU. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. Int J Methods Psychiatr Res. 2012;21(3):169-184.
3. Greenberg PE, Birnbaum HG. The economic burden of depression in the US: societal and patient perspectives. Expert Opin Pharmacother. 2005;6(3):369-376.
4. Kessler RC. The costs of depression. Psychiatr Clin North Am. 2012;35(1):1-14.
5. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917.
6. Schachter SC, Schmidt D. Vagus Nerve Stimulation. London, England: Martin Dunitz; 2001.
7. Ben-Menachem E, Hellstrom K, Verstappen D. Analysis of direct hospital costs before and 18 months after treatment with vagus nerve stimulation therapy in 43 patients. Neurology. 24 2002;59(6 Suppl 4): S44-S47.
8. Boon P, D'Have M, Van Walleghem P, et al. Direct medical costs of refractory epilepsy incurred by three different treatment modalities: a prospective assessment. Epilepsia. 2002;43(1):96-102.
9. Bernstein AL, Hess T. Vagus nerve stimulation therapy for pharmacoresistant epilepsy: effect on health care utilization. Epilepsy Behav. 2007;10(1):134-137.
10. Helmers SL, Duh MS, Guerin A, et al. Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy. Epilepsy Behav. 2011;22(2):370-375.
11. Helmers SL, Duh MS, Guerin A, et al. Clinical outcomes, quality of life, and costs associated with implantation of vagus nerve stimulation therapy in pediatric patients with drug-resistant epilepsy. Eur J Paediatr Neurol. 2012;16(5):449-458.
12. Cohen LJ, Allen JC Jr. Estimating the potential savings with vagus nerve stimulation for treatment-resistant depression: a payer perspective. Curr Med Res Opin. 2008;24(8):2203-2217.
13. Feldman RL, Dunner DL, Muller JS, Stone DA. Medicare patient experience with vagus nerve stimulation for treatment-resistant depression. J Med Econ. 2013;16(1):62-74.
14. Martin JL, Martin-Sanchez E. Systematic review and meta-analysis of vagus nerve stimulation in the treatment of depression: variable results based on study designs. Eur Psychiatry. 2012;27(3):147-155.
15. Daban C, Martinez-Aran A, Cruz N, Vieta E. Safety and efficacy of Vagus Nerve Stimulation in treatment-resistant depression. A systematic review. J Affect Disord. 2008;110(1-2):1-15.
16. Aaronson ST, Carpenter LL, Conway CR, et al. Vagus nerve stimula- tion therapy randomized to different amounts of electrical charge for treatment-resistant depression: acute and chronic effects. Brain Stimul. Epub October 23, 2012.
17. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-389.
18. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare; 1976.
19. Rush AJ, George MS, Sackeim HA, et al. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry. 2000;47(4):276-286.
20. Nahas Z, Marangell LB, Husain MM, et al. Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry. 2005;66(9):1097-1104.
21. Sackeim HA, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology. 2001;25(5):713-728.
22. Rush AJ, Marangell LB, Sackeim HA, et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry. 2005;58(5):347-354.
23. Rush AJ, Sackeim HA, Marangell LB, et al. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry. 2005;58(5):355-363.
24. Schlaepfer TE, Frick C, Zobel A, et al. Vagus nerve stimulation for depression: efficacy and safety in a European study. Psychol Med. 2008; 38(5):651-661.
25. Bajbouj M, Merkl A, Schlaepfer TE, et al. Two-year outcome of vagus nerve stimulation in treatment-resistant depression. J Clin Psychopharmacol. 2010;30(3):273-281.
26. Dunner DL, Rush AJ, Russell JM, et al. Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatmentresistant depression. J Clin Psychiatry. 2006;67(5):688-695.
27. George MS, Rush AJ, Marangell LB, et al. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry. 2005;58(5):364-373.
28. Guidelines for ATC Classification and DDD Assignment 2011. Oslo: World Health Organization (WHO) Collaborating Centre for Drug Statistics Methodology; 2010. Available from: http://www.whocc.no/filearchive/ publications/2011guidelines.pdf. Accessed 24 January 2012.
29. Berry SM, Carlin BP, Lee JJ, Muller P. Bayesian Adaptive Methods for Clinical Trials. Vol 38. Boca Raton, FL: CRC Press; 2010.
30. West M, Harrison J. Bayesian Forecasting and Dynamic Models. New York, NY: Springer-Verlag; 1977.
31. McQuay HJ, Moore RA. Using numerical results from system- atic reviews in clinical practice. Ann Intern Med. 1997;126(9): 712-720.
32. Pagnin D, de Queiroz V, Pini S, Cassano GB. Efficacy of ECT in depression: a meta-analytic review. J ECT. 2004;20(1):13-20.
33. Sackeim HA, Haskett RF, Mulsant BH, et al. Continuation pharmacotherapy in the prevention of relapse following elec- troconvulsive therapy: a randomized controlled trial. JAMA. 2001;285(10):1299-1307.
34. Morris GL 3rd, Mueller WM. Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. The Vagus Nerve Stimulation Study Group E01-E05. Neurology. 1999;53(8): 1731-1735.
35. UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet. March 8, 2003;361(9360):799-808.
36. Santermans L, Vanderbruggen N, Zeeuws D, Baeken C. Successful ECT treatment after relapse during VNS therapy. Psychiatr Danub. 2010;22 Suppl 1:S166.
37. Warnell RL, Elahi N. Introduction of vagus nerve stimulation into a maintenance electroconvulsive therapy regimen: a case study and cost analysis. J ECT. 2007;23(2):114-119.
38. Burke MJ, Husain MM. Concomitant use of vagus nerve stimulation and electroconvulsive therapy for treatment-resistant depression. J ECT. 2006;22(3):218-222.
39. Dierckx B, Heijnen WT, van den Broek WW, Birkenhager TK. Efficacy of electroconvulsive therapy in bipolar versus unipolar major depression: a meta-analysis. Bipolar Disord. 2012;14(2): 146-150.
40. Heijnen WT, Birkenhager TK, Wierdsma AI, van den Broek WW. Antidepressant pharmacotherapy failure and response to subsequent electroconvulsive therapy: a meta-analysis. J Clin Psychopharmacol. 2010;30(5):616-619.
41. Sackeim HA, Prudic J, Devanand DP, et al. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch Gen Psychiatry. 2000;57(5):425-434.
42. Sackeim HA, Brannan SK, Rush AJ, George MS, Marangell LB, Allen J. Durability of antidepressant response to vagus nerve stimulation (VNS). Int J Neuropsychopharmacol. 2007;10(6):817-826.
43. October 8, 2010: Neurological Devices Panel Meeting FDA Generated Materials. Silver Spring, MD: US Food and Drug Administration; 2010. Available from: http://www.fda.gov/AdvisoryCommittees/Committees-MeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/NeurologicalDevicesPanel/ucm202072.htm. Accessed January 24, 2012.
44. CST95 Coding Symbols for Thesaurus of Adverse Reaction Terms (COSTART). 5th ed. Rockville, MD: U.S. Food and Drug Administration; Center for Drug Evaluation and Research; 1995.